5-Morpholinopyridin-3-amine → 2-(4-cyclohexylpiperazin-1-yl)-5,7-difluoro-3-methyl-N-(5-morpholinopyridin-3-yl)quinolin-4-amine

Participants

Reaction Steps

Essentially prepared according to Procedure H using 4-chloro-2-(4-cyclohexylpiperazin-1-yl)-5,7-difluoro-3-methylquinoline (22.0 mg, 0.058 mmol) and 5-morpholinopyridin-3-amine in toluene to give 2-(4-cyclohexylpiperazin-1-yl)-5,7-difluoro-3-methyl-N-(5-morpholinopyridin-3-yl)quinolin-4-amine. 1H NMR (CDCl3) δ ppm 7.93 (1H, d, J=2.3 Hz), 7.70 (1H, d, J=1.8 Hz), 7.27-7.33 (1H, m), 6.86 (1H, d, J=12.9 Hz), 6.78 (1H, ddd, J=13.9, 8.6, 2.5 Hz), 6.57 (1H, t, J=2.3 Hz), 3.79-3.91 (4H, m), 3.35-3.61 (4H, m), 3.07-3.23 (4H, m), 2.70-2.98 (4H, m), 2.06 (3H, s), 1.91-2.03 (2H, m), 1.77-1.91 (2H, m), 1.67 (1H, d, J=12.9 Hz), 1.05-1.41 (6H, m). Mass Spectrum (ESI) m/e=524.3 (M+1).

Provenance & Evidence